AbbVie Inc.'s Q2 2025 results showcase Skyrizi & Rinvoq's growth, strong finances, and a promising pipeline. Click for my ...

This was the stock's second consecutive day of gains.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie, in collaboration with REGENXBIO Inc., is ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

The global biopharma firm will build a new API production facility near its global headquarters in North Chicago.

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net income ...